MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

Search

Adaptive Biotechnologies Corp

Uždarymo kaina

10.81 -1.91

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

10.57

Max

11.22

Pagrindiniai rodikliai

By Trading Economics

Pajamos

3.9M

-30M

Pardavimai

5M

52M

Pelno marža

-56.881

Darbuotojai

619

EBITDA

-3.3M

-30M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+2.68% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-07-31

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

629M

1.8B

Ankstesnė atidarymo kaina

12.72

Ankstesnė uždarymo kaina

10.81

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bullish Evidence

Adaptive Biotechnologies Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-15 23:41; UTC

Rinkos pokalbiai

Nikkei May Trade in Range Amid Tariff Uncertainty -- Market Talk

2025-07-15 23:40; UTC

Rinkos pokalbiai

Gold Edges Higher on Possible Position Adjustments -- Market Talk

2025-07-15 23:05; UTC

Rinkos pokalbiai

Auckland International Airport Passenger Growth May Disappoint Again -- Market Talk

2025-07-15 21:36; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-07-15 21:36; UTC

Rinkos pokalbiai

Canada CPI Data Fuel Rate-Prediction Revisions -- Market Talk

2025-07-15 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-07-15 20:50; UTC

Rinkos pokalbiai
Uždarbis

Financial Services Roundup: Market Talk

2025-07-15 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-07-15 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-07-15 20:14; UTC

Įsigijimai, susijungimai, perėmimai

Chinese EV Makers to Combine. Geely Is Buying Zeekr. -- Barrons.com

2025-07-15 20:07; UTC

Uždarbis

BlackRock Shares Tumble After Big Client Redemption Blunts Quarterly Results -- Update

2025-07-15 20:06; UTC

Rinkos pokalbiai

Nvidia, AMD Seen Benefiting from Return to Chinese Chip Sales -- Market Talk

2025-07-15 19:54; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-07-15 19:54; UTC

Rinkos pokalbiai

Meta CEO Hints at Higher Revenues, Expenses With Data Center Plans -- Market Talk

2025-07-15 19:38; UTC

Rinkos pokalbiai

Oil Falls As Eventual Oversupply Concerns Weigh -- Market Talk

2025-07-15 19:09; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Back-to-Back Gains -- Market Talk

2025-07-15 19:07; UTC

Rinkos pokalbiai

Canada CFOs Willing to Take Risks, Increase Spending -- Market Talk

2025-07-15 19:03; UTC

Rinkos pokalbiai

Gold Slips as Big Buyers Pull Back -- Market Talk

2025-07-15 18:32; UTC

Įsigijimai, susijungimai, perėmimai

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

2025-07-15 18:31; UTC

Įsigijimai, susijungimai, perėmimai

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

2025-07-15 18:13; UTC

Rinkos pokalbiai

Canada Adopts 'Note of Realism' in US Trade Talks, Setting Stage for Possible Tariff Deal -- Market Talk

2025-07-15 17:40; UTC

Rinkos pokalbiai

Canadian Inflation Adds to Case for Bank of Canada Extending Pause -- Market Talk

2025-07-15 17:40; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-07-15 17:25; UTC

Įsigijimai, susijungimai, perėmimai

National Fuel Gas Gets Rare Double Upgrade. Buy the Stock, Analyst Says. -- Barrons.com

2025-07-15 17:24; UTC

Rinkos pokalbiai

Dollar Gains Strength After Inflation Data -- Market Talk

2025-07-15 16:49; UTC

Rinkos pokalbiai

Oil Futures Likely to Continue Sideways Trade -- Market Talk

2025-07-15 16:20; UTC

Rinkos pokalbiai
Uždarbis

Financial Services Roundup: Market Talk

2025-07-15 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-07-15 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-07-15 15:42; UTC

Rinkos pokalbiai

Coca-Cola Seen as Top Pick Ahead of Consumer Staples Earnings -- Market Talk

Akcijų palyginimas

Kainos pokytis

Adaptive Biotechnologies Corp Prognozė

Kainos tikslas

By TipRanks

2.68% į viršų

12 mėnesių prognozė

Vidutinis 11.86 USD  2.68%

Aukščiausias 15 USD

Žemiausias 9 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Adaptive Biotechnologies Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

8 ratings

7

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

8.81 / 10.18Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bullish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Weak Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.